Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

Autor: Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst, Anne T. Gelderloos, Renée Poels, Fengzhi Li, Richard W. J. Groen, Sonja Zweegman, Niels W. C. J. van de Donk, Michael O’Dwyer, Tuna Mutis

Publikováno v: HemaSphere, Vol 5, Iss 5, p e561 (2021)

We have recently shown the strong negative impact of multiple myeloma (MM)-bone marrow mesenchymal stromal cell (BMMSC) interactions to several immunotherapeutic strategies including conventional T cells, chimeric antigen receptor (CAR) T cells, and

Externí odkaz: https://doaj.org/article/58b52a303c724b53a0467fbcccf06ef7

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Autor: Lisa C. Holthof, Hilma J. van der Horst, Susan E. van Hal-van Veen, Ruud W.J. Ruiter, Fengzhi Li, Marijke Buijze, Morten N. Andersen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Henk M. Lokhorst, Sonja Zweegman, Richard W.J. Groen, Tuna Mutis

Publikováno v: Haematologica, Vol 105, Iss 2 (2020)

Externí odkaz: https://doaj.org/article/32a48816b4834d20b9869cc1a06297bd

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Autor: Sonja Zweegman, Anne T. Gelderloos, Esther C.W. Breij, Inger S. Nijhof, Tuna Mutis, Hilma J. van der Horst, Marije B. Overdijk, Martine E D Chamuleau

Publikováno v: van der Horst, H J, Gelderloos, A T, Chamuleau, M E D, Breij, E C W, Zweegman, S, Nijhof, I S, Overdijk, M B & Mutis, T 2021, ' Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma ', Blood, vol. 5, no. 8, pp. 2165-2172 . https://doi.org/10.1182/BLOODADVANCES.2020003731
Blood Adv
Blood, 5(8), 2165-2172. American Society of Hematology

Apoptosis induction by death receptor (DR)-specific agonistic antibodies is a potentially effective antitumor therapy. Nonetheless, to date, all conventional DR-targeting antibodies that induce apoptosis via FcγR-dependent DR clustering failed to sh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ebbd19120d9f0155a225c20e7061bf0
http://www.scopus.com/inward/record.url?scp=85106295701&partnerID=8YFLogxK

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Autor: Ida H. Hiemstra, Hilma J. van der Horst, Martine E.D. Chamuleau, A. Vera de Jonge, Margaretha G. M. Roemer, Tuna Mutis, Hendrik F. van Essen, Daniella R. A. I. Berry, Anne T. Gelderloos, Nathalie J. Hijmering, Sonja Zweegman, Daphne de Jong, Esther C.W. Breij

Publikováno v: Blood Cancer Journal
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0a7136b198a975ec95c1bb3014164d
http://europepmc.org/articles/PMC7892878

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

Autor: Esther C.W. Breij, Hilma J. van der Horst, Simone C. Oostindie, Sonja Zweegman, Martine E D Chamuleau, Inger S. Nijhof, Marije B. Overdijk, Saskia A. G. M. Cillessen, Tuna Mutis, Anne T. Gelderloos

Publikováno v: HemaSphere
HemaSphere, 5(1). Wolters Kluwer Health
HemaSphere, Vol 5, Iss 1, p e504 (2021)
Van Der Horst, H J, Oostindie, S C, Cillessen, S A G M, Gelderloos, A T, Overdijk, M B, Nijhof, I S, Zweegman, S, Chamuleau, M E D, Breij, E C W & Mutis, T 2021, ' Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies ', HemaSphere, vol. 5, no. 1, pp. E504 . https://doi.org/10.1097/HS9.0000000000000504

Supplemental Digital Content is available in the text.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f889d7418b64dcdd8f08c84d9cb32d23
http://europepmc.org/articles/PMC7732266